Omnicell (NASDAQ:OMCL) EVP Sells $129,010.00 in Stock

Key Points

• Corey Manley, the Executive Vice President of Omnicell, sold 3,880 shares of stock at an average price of $33.25, totaling approximately $129,010, which reduced his ownership by 3.39%.
• Omnicell's Q2 earnings beat expectations, reporting $0.45 EPS against a consensus estimate of $0.30, alongside a year-over-year revenue increase of 5% to $290.56 million.
• The stock has seen recent rating adjustments, with Wall Street Zen downgrading it to a "buy" and various firms adjusting their target prices, reflecting a current average target price of $46.71.

Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) EVP Corey J. Manley sold 3,880 shares of the business's stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $33.25, for a total value of $129,010.00. Following the completion of the sale, the executive vice president owned 110,653 shares of the company's stock, valued at approximately $3,679,212.25. This represents a 3.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Omnicell Stock Performance

NASDAQ OMCL traded down $0.46 on Friday, reaching $31.34. The stock had a trading volume of 1,383,338 shares, compared to its average volume of 488,885. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $55.74. The business's 50-day moving average price is $30.95 and its 200 day moving average price is $30.84. The stock has a market cap of $1.44 billion, a P/E ratio of 62.68, a price-to-earnings-growth ratio of 6.84 and a beta of 0.82.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The company had revenue of $290.56 million during the quarter, compared to analysts' expectations of $275.57 million. During the same quarter in the previous year, the business earned $0.51 earnings per share. The firm's revenue for the quarter was up 5.0% on a year-over-year basis. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, equities analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Wall Street Analyst Weigh In

OMCL has been the subject of a number of research reports. Wells Fargo & Company boosted their price objective on Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research note on Monday, July 21st. Bank of America upped their price target on Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, May 23rd. Piper Sandler cut their price target on Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, August 11th. Finally, Wall Street Zen cut Omnicell from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $46.71.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Raymond James Financial Inc. purchased a new position in Omnicell in the second quarter worth $26,000. GAMMA Investing LLC raised its position in Omnicell by 37.1% in the second quarter. GAMMA Investing LLC now owns 1,694 shares of the company's stock worth $50,000 after acquiring an additional 458 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Omnicell by 385.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company's stock worth $146,000 after acquiring an additional 3,932 shares in the last quarter. AlphaQuest LLC grew its holdings in Omnicell by 79.0% in the first quarter. AlphaQuest LLC now owns 6,400 shares of the company's stock valued at $224,000 after purchasing an additional 2,824 shares during the last quarter. Finally, New Age Alpha Advisors LLC acquired a new stake in Omnicell in the first quarter valued at $233,000. Hedge funds and other institutional investors own 97.70% of the company's stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.